Crohn's disease

AbbVie Showcases Breadth and Depth of Research in Crohn's Disease and Ulcerative Colitis at UEG Week 2023

Retrieved on: 
Tuesday, October 10, 2023
Congress, NYSE, United European Gastroenterology, UC, Ustekinumab, Abstract, INSPIRE, Inflammation, CD, MD, Maintenance, ABBV, IBD, Crohn's disease, Safety, University, AbbVie, Medicine, NORTH, CEST, Ulcerative colitis, Patient, Risankizumab, Inflammatory Bowel Diseases, Research, UEG, University of Calgary, Doctor of Pharmacy, Boehringer Ingelheim, Poster, Pharmaceutical industry

NORTH CHICAGO, Ill., Oct. 10, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will share new data from its robust gastroenterology portfolio at the United European Gastroenterology (UEG) Week 2023 Congress taking place in Copenhagen, Denmark from October 14-17. AbbVie will showcase a total of 23 abstracts, including a late-breaker, with 11 oral presentations and 12 poster presentations spanning research on risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) in both Crohn's disease (CD) and ulcerative colitis (UC).

Key Points: 
  • AbbVie will showcase a total of 23 abstracts, including a late-breaker, with 11 oral presentations and 12 poster presentations spanning research on risankizumab (SKYRIZI®) and upadacitinib (RINVOQ®) in both Crohn's disease (CD) and ulcerative colitis (UC).
  • "Our continued commitment to research in IBD demonstrates our relentless quest to elevating standards of care for those living with disruptive gastroenterological conditions," said Sofie Berg, PharmD, Ph.D., head of gastroenterology, global medical affairs, AbbVie.
  • "The research that will be presented by AbbVie at UEG Week 2023 will advance knowledge to better address how new therapies may further benefit patients with these challenging conditions with the aim to maximize clinical and endoscopic outcomes."
  • SKYRIZI® (risankizumab) is part of a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialization globally.

IVX Health Opens Two New Infusion Centers to Serve Patients in Little Rock

Retrieved on: 
Thursday, October 5, 2023
Diagnosis, Crohn's disease, Health, Rheumatoid arthritis, Immunodeficiency, ROCK, Gastroenterology, IVX, Rheumatology, Multiple sclerosis, Wi-Fi, Neurology, Patient, Sclerosis, Practitioner, Nursing, Medical device

LITTLE ROCK, Ark., Oct. 5, 2023 /PRNewswire/ -- IVX Health , a national provider of outpatient infusion and injection centers, today announced the opening of two new infusion centers in the greater Little Rock area.

Key Points: 
  • LITTLE ROCK, Ark., Oct. 5, 2023 /PRNewswire/ -- IVX Health , a national provider of outpatient infusion and injection centers, today announced the opening of two new infusion centers in the greater Little Rock area.
  • The two new Little Rock centers complement IVX Health's existing footprint in Arkansas and across the Midwest .
  • "IVX Health provides top-notch care for patients and referring physicians, with a commitment to clinical excellence and a truly world-class patient experience," said Ashley Riley, regional vice president at IVX Health.
  • All IVX Health patients are guaranteed a private infusion suite, equipped with the same safety protocols as a traditional hospital infusion setting.

Microfluidics Market Size to Expand at a CAGR of 16.5% to Reach Valuation of USD 73.16 Billion by 2028 | Brandessence Market Research

Retrieved on: 
Wednesday, October 4, 2023
Credible, DNA, Drug development, Crohn's disease, Independent Healthcare Providers Network, Institute for Anarchist Studies, Disease, Biotechnology, Research, Genomics, Proteomics, Future, Environmental monitoring, Miniaturization, Page, Investment, Treatment, Drug discovery, Parkinson's disease, Growth, Alzheimer's disease, Nanotechnology, Automation, Medical imaging, Pharmaceutical industry, Medical device, Fine chemical, Microfluidics

Researchers and industry players are continually striving to develop smaller, more efficient microfluidic devices that can automate complex tasks.

Key Points: 
  • Researchers and industry players are continually striving to develop smaller, more efficient microfluidic devices that can automate complex tasks.
  • The ability to conduct rapid and accurate tests using portable devices is a game-changer, particularly in remote or resource-limited settings.
  • This trend is expected to expand, driven by the need for quick and accessible healthcare solutions.
  • Microfluidic devices offer precise control over small quantities of fluids, making them invaluable in medical research and diagnostics.

Microfluidics Market Size to Expand at a CAGR of 16.5% to Reach Valuation of USD 73.16 Billion by 2028 | Brandessence Market Research

Retrieved on: 
Wednesday, October 4, 2023
Credible, DNA, Drug development, Crohn's disease, Independent Healthcare Providers Network, Institute for Anarchist Studies, Disease, Biotechnology, Research, Genomics, Proteomics, Future, Environmental monitoring, Miniaturization, Page, Investment, Treatment, Drug discovery, Parkinson's disease, Growth, Alzheimer's disease, Nanotechnology, Automation, Medical imaging, Pharmaceutical industry, Medical device, Fine chemical, Microfluidics

Researchers and industry players are continually striving to develop smaller, more efficient microfluidic devices that can automate complex tasks.

Key Points: 
  • Researchers and industry players are continually striving to develop smaller, more efficient microfluidic devices that can automate complex tasks.
  • The ability to conduct rapid and accurate tests using portable devices is a game-changer, particularly in remote or resource-limited settings.
  • This trend is expected to expand, driven by the need for quick and accessible healthcare solutions.
  • Microfluidic devices offer precise control over small quantities of fluids, making them invaluable in medical research and diagnostics.

EnLiSense CCM To Advance IBD Care with Innovative Sweat Sensor Studies, Teams Up with Leading Clinicians

Retrieved on: 
Wednesday, October 4, 2023
Technology, Biotechnology, Health, Other Health, Professional Services, Research, Medical Devices, Software, General Health, Data Analytics, Genetics, Health Technology, Science, Data Management, Brain-derived neurotrophic factor, University, Crohn's & Colitis Foundation, GFAP, IBD, University of Texas at Austin, Melatonin, Interleukin 6, Biomarker, Glial fibrillary acidic protein, IL6, University of Glasgow, Crohn's disease, Patient, CRP, Physician, Conditional sentence, Inflammatory bowel disease, BDNF, Glucose, Skin, C-reactive protein, Pharmaceutical industry, Medical imaging, Cortisol, Calprotectin, CCM

Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.

Key Points: 
  • Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.
  • The IBD Aware system, a cornerstone of EnLiSense's innovative approach, continuously monitors key inflammatory biomarkers by gently resting on a patient’s skin sampling just nano-liters of passive sweat.
  • This non-invasive, wearable technology empowers both clinicians and patients with real-time data, facilitating personalized, data-driven, proactive management of chronic diseases like IBD.
  • Dr. Sriram Muthukumar, CEO of EnLiSense CCM, reflects on the early findings, stating, "The initial validation data is indeed very encouraging.

Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment

Retrieved on: 
Wednesday, October 4, 2023
Biotechnology, Pharmaceutical, Health, Teva Pharmaceuticals, TEVA, Teva, Crohn's disease, Diarrhea, IBD, Disease, TEV, Weight loss, Inflammation, Abdominal pain, Ulcerative colitis, Science, Pivot, Inflammatory bowel disease, SAN, TASE, SNY, GI, NYSE, Fatigue, Pharmaceutical industry, Fine chemical, Sanofi

Inflammatory bowel disease (IBD) is the term for two conditions -- Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal (GI) tract. Prolonged inflammation results in damage to the GI tract. The common symptoms for both conditions are persistent diarrhea, rectal bleeding, abdominal pain, fatigue, and weight loss. An estimated ~10 million people worldwide live with IBD.

Key Points: 
  • Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
  • This collaboration further validates the great science that Teva has to offer with our internally developed anti-TL1A.
  • Inflammatory bowel disease (IBD) is the term for two conditions -- Crohn’s disease and ulcerative colitis – characterized by chronic inflammation of the gastrointestinal (GI) tract.
  • Teva will hold an investor call and live webcast today (Wednesday, October 4, 2023) at 8:00 a.m.

THE AUTOIMMUNE ASSOCIATION ANNOUNCES ITS ANNUAL COMMUNITY SUMMIT FOR PATIENTS AND CARE PROVIDERS

Retrieved on: 
Tuesday, October 3, 2023
Ohio State University, Diet, Education, Sjögren syndrome, Woman, Public policy, Research, Lupus, Cell, Colitis, Multiple sclerosis, EDT, Crohn's disease, Pain, Fatigue, Autoimmunity, Autoimmune disease, Patient, Physician, Immune system, Mental health, Rheumatoid arthritis, Vaccine, Nursing

CLINTON TOWNSHIP, Mich., Oct. 3, 2023 /PRNewswire/ -- The Autoimmune Association, the world's leading nonprofit organization dedicated to autoimmune awareness, advocacy, education, and research, announces its third annual Autoimmune Community Summit on Thursday, October 5 and Friday, October 6, 2023.

Key Points: 
  • This annual free, virtual event is open to anyone affected by autoimmune disease to share information, be inspired, create new connections and learn about the latest treatments.
  • While the exact cause of autoimmune diseases is not fully understood, they are thought to result from a combination of genetic and environmental factors.
  • This two-day event, designed for patients and care partners, offers educational and empowering sessions led by autoimmune experts including scientists and researchers, physicians, mental health experts, policy leaders and patient advocates.
  • The Autoimmune Community Summit will take place from 11:30 a.m. to 3:00 p.m. EDT on Thursday, October 5 and Friday October 6.

ProciseDx Announces the First FDA-cleared Therapeutic Drug Monitoring Tests for Biologic Drugs, Humira®, Remicade®, and their Biosimilars

Retrieved on: 
Tuesday, October 3, 2023
Therapeutic drug monitoring, Serum, Doctor of Philosophy, Hospital, MD, Patient, CRP, American College, TDM, University, Infliximab, Laboratory, Joshua Casteel, FDA, Workflow, Adalimumab, Energy, Ulcerative colitis, Crohn's disease, SAN, IBD, ADL, Pharmaceutical industry, Medical device

SAN DIEGO, Oct. 3, 2023 /PRNewswire/ -- ProciseDx Inc. announces that it has been granted de novo FDA clearance for the therapeutic drug monitoring (TDM) tests for adalimumab (Humira® and biosimilar Amgevita®) and infliximab (Remicade® and biosimilars Inflectra® and Renflexis®).

Key Points: 
  • SAN DIEGO, Oct. 3, 2023 /PRNewswire/ -- ProciseDx Inc. announces that it has been granted de novo FDA clearance for the therapeutic drug monitoring (TDM) tests for adalimumab (Humira® and biosimilar Amgevita®) and infliximab (Remicade® and biosimilars Inflectra® and Renflexis®).
  • ProciseDx expects to commercialize these first FDA-cleared infliximab and adalimumab drug monitoring tests in Q4 2023.
  • The tests can be performed using serum and take only 5 minutes to obtain a quantitative result.
  • "The ProciseDx platform will change that, with a simple workflow producing a reliable quantitative measurement in 5 minutes or less.

SetPoint Medical Announces Publication of Data for Neuroimmune Modulation to Treat Crohn's Disease in Journal of Crohn's and Colitis

Retrieved on: 
Tuesday, October 3, 2023
Biotechnology, Health, Clinical Trials, Medical Devices, RA, Defecation, TNF, Gastrointestinal tract, Vagus nerve, Serum, Disease, Quality of life, Vagus nerve stimulation, Inflammation, Doctor of Philosophy, Rheumatoid arthritis, Inflammatory bowel disease, Crohn's disease, Journal, Medical director, MD, Patient, Gastroenterology, CDAI, Safety, Northwestern, Pharmaceutical industry, Colitis, Medicine

SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the publication of data from a multicenter European clinical trial evaluating the safety and efficacy of neuroimmune modulation in patients with treatment-refractory Crohn’s disease in the Journal of Crohn’s and Colitis .

Key Points: 
  • SetPoint Medical , a clinical-stage healthcare company dedicated to patients with chronic autoimmune diseases, today announced the publication of data from a multicenter European clinical trial evaluating the safety and efficacy of neuroimmune modulation in patients with treatment-refractory Crohn’s disease in the Journal of Crohn’s and Colitis .
  • The pilot study demonstrated that neuroimmune modulation via vagus nerve stimulation resulted in a clinically meaningful reduction in disease activity and improved quality of life.
  • “Crohn’s disease is a debilitating inflammatory condition affecting the gastrointestinal tract.
  • “We are committed to advancing the potential of neuroimmune modulation for patients suffering from various chronic autoimmune conditions,” said Murthy V. Simhambhatla, Ph.D., president and CEO of SetPoint Medical.

New Research by Draper and Pfizer Demonstrates Colon-on-Chip Tissue Models

Retrieved on: 
Monday, October 2, 2023
Science, Failure, Micropump, Diarrhea, IBD, Malnutrition, Toxicity, Research, Multimedia, Inflammation, Abdominal pain, Ulcerative colitis, Colon, Lung, Inflammatory bowel disease, Crohn's disease, Incidence, Scientific Reports, Electrode, Permeability, Anemia, Irritation, Immune system, Drug discovery, Kidney, Liver, Patient, Health, Recurrence, Common, Gum arabic, Pharmaceutical industry, Medical imaging, Draper, Pfizer

CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire-PRWeb/ -- Science is stalled in its efforts to develop more effective treatments for inflammatory bowel disease (IBD), in part because most treatments focus on reducing inflammation but ignore the importance of repairing the bowel's epithelial barrier. Now, new research suggests that science might want to pursue a mix of both strategies in addressing IBD—restore the intestinal barrier to a healthy state and reduce inflammation. Patients could see improved outcomes and reach higher treatment response rates.

Key Points: 
  • IBD, which includes both ulcerative colitis and Crohn's disease, is increasing around the world, with an incidence rate of 4.9M cases worldwide .
  • A research team from Draper and Pfizer experimented using human organ tissues-on-a-chip.
  • The team seeded, grew and tested human colon epithelial tissue models in Draper's PREDICT96 high-throughput microfluidic testing platform.
  • Unlike most microfluidic testing platforms that have fewer than a dozen replicates, Draper's platform can hold 96 individual organ tissue models in one microfluidic culture plate.